Publication date: May 13, 2019
This means that PPMS patients living in the U. K. will now have access to Ocrevus treatment through the country’s National Health Service (NHS). In the meantime, Genentech, a member of the Roche group – Ocrevus’ manufacturer – will work closely with the NHS in Wales and Northern Ireland, and the Scottish Medicines Consortium in Scotland, to ensure Ocrevus becomes available in all of the U. K. Ocrevus is the first approved NHS treatment for PPMS in the U. K., a landmark decision made possible only with the collective effort, and dedication, of MS support organizations, including the MS Trust, patients and physicians, a trust official said. The NHS in England now will have three months to prepare before it starts funding the treatment for all eligible PPMS patients receiving Ocrevus prescriptions from their doctors. The post Ocrevus Approved in UK as First NHS Treatment for PPMS appeared first on Multiple Sclerosis News Today.
|disease||MESH||primary progressive multiple sclerosis|
- #AANAM – Greater Exposure to Ocrevus Means Less Risk of Disability Progression in MS Patients, Study Contends
- NHS England strikes deal to make innovative Multiple Sclerosis drug available, paving the way for NICE recommendation